Methodology Patients (n=49) undergoing maximal-effort upfront-debulking surgery for advanced HGSOOC had a tumour mapping of their tumour dissemination. Tumour biopsies were collected (range 4–15) from patients, and also at time of relapse (n=10 patients). DNA was extracted from tumours (5 per patient, n=49 patients plus paired relapse samples) and Illumina Human OmniExpress genotyping performed. Allele-specific copy number (CN) was quantified using ASCAT. CN signature exposures were determined for all samples. Homologous recombination (HR) scores were estimated using a scarHRD algorithm, applying a cut-off >42 for HR-deficient.

Results Extensive genomic variations in CN signature exposures for different patients’ tumours were observed, including between matched primary and relapse tumours. Increased CN signature exposure scores for Signatures 2 (p=0.00017), 4 (p=0.0029) and 6 (p=0.001) correlated with poor outcome in platinum-resistant/refractory patients, increased Signature 3 correlated with favourable outcome (p=0.00018) for platinum-sensitive and no-relapse patients. Variations in HR scores were observed across the cohort with one fifth of patients presenting with a mixed HR score profile across their tumour deposits, demonstrating both HR-deficient and HR-proficient tumours within patients.

Conclusion Extensive CN variations in CN signature scores and mixed HR-deficiency/proficiency scores indicates that a single tumour biopsy does not accurately depict disseminated HGSOOC biology, and therefore should not be used as the basis to derive biomarker profiles for prediction of patient treatment responses or outcomes.

2022-RA-1651-ESGO EPITHELIAL OVARIAN CANCER IS INFILTRATED BY ACTIVATED EFFECTOR T CELLS COEXPRESSING MULTIPLE INHIBITORY RECEPTORS AND BY MYELOID CELLS EXPRESSING INHIBITORY RECEPTOR LIGANDS

1Alice Bergamini, 2Elena Tassi, 3Miriam Sant’Angelo, 4Chiara Balestrieri, 5Emanuela Brunetto, 6Mimria Redegalli, 7Alessia Potenza, 8Danilo Abbati, 9Francesco Manfredi, 10Maria Giulia Cangi, 11Luca Bocciolone, 12Giorgio Candotti, 13Emanuela Rabietti, 14Gianluca Taccagni, 15Massimo Candiani, 16Claudio Doglioni, 17Gispa Mangili, 18Chiara Bonini. Obstetrics and Gynecology, Università Vita-Salute San Raffaele; 19IRCCS Ospedale San Raffaele, MILANO, Italy; 20Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Disease, San Raffaele Scientific Institute, Milano, Italy; 21Department of Surgical Pathology, IRCCS Ospedale San Raffaele, Milano, Italy; 22Center for Omics Sciences, IRCCS Ospedale San Raffaele, Milano, Italy; 23Obstetrics and Gynecology, IRCCS Ospedale San Raffaele, Milano, Italy

10.1136/ijgc-2022-ESGO.901

Introduction/Background Advanced Lung Cancer Inflammation Index (ALI) reflects systemic inflammation and has been shown to be a prognostic factor for lung cancer patients undergoing surgery. No previous study has assessed the prognostic significance of ALI in patients with ovarian cancer (OC). This study aimed to explore the relationship between ALI and prognosis of OC.

Methodology Electronic records of 83 patients with OC who underwent primary debulking surgery (PDS) at Tata Medical Center between 2017 and 2018 were reviewed. Patients treated with primary chemotherapy and those treated with palliative intent were excluded. The ALI score was calculated as body mass index x serum albumin/neutrophil to lymphocyte ratio. A web-based programme [Cutoff Finder (http://molpath.charite.de/cutoff)] was used to deduce the appropriate cut-off value for ALI. The Kaplan-Meier method and Cox Proportional Hazards model were used to compare survival among prognostic groups.

Results The optimal cut-off value of ALI was determined as 12.5. Among the 83 patients, 10 had low ALI (<12.5), and 73 had high ALI (≥12.5). The low-ALI group had more complications of Clavien-Dindo grade 3 or higher after PDS (P=0.04). The patients with low ALI had higher chances of 30-day-mortality following PDS compared to the high-ALI group (P=.005). Median relapse-free survival (RFS) in the low-ALI group was 9 months compared to 32 months in the high-ALI group (hazard ratio [HR] for relapse, 0.16; P<0.001). Median overall survival (OS) in the low-ALI group was 20 months, and in the high-ALI group median OS was 56 months (HR 0.12, P<0.001).